Greenbrook TMS Inc. Overview
Pro stress-test →Greenbrook TMS Inc. operates a network of outpatient mental health treatment centers specializing in Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray) for treatment-resistant depression and major depressive disorder. The company has delivered over one million treatments to more than 27,000 patients across the United States.
Strategic Profile
Pro stress-test →Greenbrook is a leading provider of FDA-cleared, non-invasive mental health therapies positioned in the growing behavioral health market. The company has faced significant liquidity challenges and capital structure stress, recently transitioning to OTC trading after delisting from NASDAQ in 2023, though it now trades on OTC markets as GBNHF.
Competitive Landscape
Pro stress-test →Greenbrook competes with other TMS and mental health service providers including Neuronetics (STIM), which agreed to acquire the company. The broader mental health services market includes traditional psychiatry practices, telepsychiatry platforms, and other non-invasive treatment providers. Greenbrook's main competitive advantage lies in its established network of treatment centers, though financial constraints limit expansion capability.
Industry Context
Greenbrook TMS Inc. operates in Healthcare Services - Mental Health Treatment.
Key facts
Founded: 2018 · Headquarters: Toronto, Canada